European journal of nuclear medicine and molecular imaging · 2026
Exploring extended [18F]FDG kinetics in lymphoma with ultra-late LAFOV-PET/CT.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Weissinger Matthias, Ursprung Stephan, Jacoby Johann, Vogel Jonas, Calderón Eduardo, Gückel Brigitte, Schmidt Fabian, Schwenck Johannes, Dittmann Helmut, Nikolaou Konstantin, Fougère Christian la, Reinert Christian Philipp
Аннотация
PURPOSE: This prospective trial investigated extended [18F]FDG kinetics in lymphoma to provide in-vivo insights into glucose metabolism with potential relevance for staging and risk stratification.
METHODS: Fifteen consecutive, treatment- naïve lymphoma patients (4 Hodgkin, 11 non-Hodgkin) underwent routine whole-body [18F]FDG-PET/CT at 1 h post injection (p.i., injected activity 3.02 ± 0.34 MBq/kg) followed by additional Long Axial Field-Of-View (LAFOV)-PET/CT scans at 3 h and 6 h p.i. (Biograph Vision Quadra®, Siemens Healthineers; acquisition 5/15/30 min). Standardised uptake values (SUV) of lymphoma, benign lymph nodes, organs and reference tissues were quantified and multi time-point kinetics were described using Retention Indices (RI) and linear/quadratic trajectory analyses. Image quality was rated by two blinded readers on a 5-point Likert scale.
RESULTS: Image quality remained diagnostic in all datasets. Median Tumour-to-Background Ratio (TBR) increased significantly from 4.1 (1 h p.i.) to 12.5 (3 h p.i.) and 23.9 (6 h p.i.), p < 0.001. High-grade lymphoma exhibited an almost linear SUV rise, whereas low-grade entities followed a parabolic course, peaking at 3 h p.i. Benign lymph nodes demonstrated constant uptake (1 h: 0.9 ± 0.3, 3 h: 0.8 ± 0.5, 6 h: 0.8 ± 0.4). RIs showed a significant increase in [18F]FDG uptake over time in lymphoma, compared with a decline in benign lymph nodes (1-3 h p.i.: 19.4% vs. -14.4%, p < 0.001).
CONCLUSION: The LAFOV scanner enables high-quality [18F]FDG PET imaging for up to 6 h p.i., with a six-fold increase of TBR in ultra-late scans 6 h p.i. Extended [18F]FDG kinetic analysis differentiates high- and low-grade lymphomas from benign lymph nodes and reveals a significant decline in tracer uptake in low-grade lymphomas between 3 and 6 h p.i.
TRIAL REGISTRATION: DRKS00027307. Registered 26 November 2021.
METHODS: Fifteen consecutive, treatment- naïve lymphoma patients (4 Hodgkin, 11 non-Hodgkin) underwent routine whole-body [18F]FDG-PET/CT at 1 h post injection (p.i., injected activity 3.02 ± 0.34 MBq/kg) followed by additional Long Axial Field-Of-View (LAFOV)-PET/CT scans at 3 h and 6 h p.i. (Biograph Vision Quadra®, Siemens Healthineers; acquisition 5/15/30 min). Standardised uptake values (SUV) of lymphoma, benign lymph nodes, organs and reference tissues were quantified and multi time-point kinetics were described using Retention Indices (RI) and linear/quadratic trajectory analyses. Image quality was rated by two blinded readers on a 5-point Likert scale.
RESULTS: Image quality remained diagnostic in all datasets. Median Tumour-to-Background Ratio (TBR) increased significantly from 4.1 (1 h p.i.) to 12.5 (3 h p.i.) and 23.9 (6 h p.i.), p < 0.001. High-grade lymphoma exhibited an almost linear SUV rise, whereas low-grade entities followed a parabolic course, peaking at 3 h p.i. Benign lymph nodes demonstrated constant uptake (1 h: 0.9 ± 0.3, 3 h: 0.8 ± 0.5, 6 h: 0.8 ± 0.4). RIs showed a significant increase in [18F]FDG uptake over time in lymphoma, compared with a decline in benign lymph nodes (1-3 h p.i.: 19.4% vs. -14.4%, p < 0.001).
CONCLUSION: The LAFOV scanner enables high-quality [18F]FDG PET imaging for up to 6 h p.i., with a six-fold increase of TBR in ultra-late scans 6 h p.i. Extended [18F]FDG kinetic analysis differentiates high- and low-grade lymphomas from benign lymph nodes and reveals a significant decline in tracer uptake in low-grade lymphomas between 3 and 6 h p.i.
TRIAL REGISTRATION: DRKS00027307. Registered 26 November 2021.